Skip to Content
Merck
  • [Clinical evaluation of a new oral penem, SY5555, in infants and children].

[Clinical evaluation of a new oral penem, SY5555, in infants and children].

The Japanese journal of antibiotics (1995-02-01)
M Kino, H Higashino, Y Kobayashi
ABSTRACT

A clinical study was performed on SY5555, a newly developed penem antibiotic, in children. SY5555 was given orally to 14 patients at 19-29 mg/kg/day in 3 doses for 4 to 12 days. Clinical evaluations were made on the 14 patients including 4 with pharyngitis, 7 with tonsillitis, one with urinary tract infection, and 2 with impetigo. Overall clinical effects were excellent in 2, good in 12, with an efficacy rate of 100%. Causative organisms (Staphylococcus aureus and Streptococcus pyogenes) were all eradicated. As to adverse reactions, mild diarrhea was observed in 4 patients. These data suggest that SY5555 is a useful oral antibiotic for the treatment of bacterial infections in children.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Faropenem sodium hydrate, ≥98% (HPLC)